Literature DB >> 9920519

Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm.

H Ohmura1, Y Watanabe, C Hatsumi, H Sato, H Daida, H Mokuno, H Yamaguchi.   

Abstract

Recent study demonstrated high susceptibility of plasma LDL to lipid peroxidative modification in patients with variant angina. Oxidized stress state, especially oxidized LDL, may induce coronary artery spasm by its impairing effect of endothelium-dependent arterial relaxation, but precise mechanisms remain unclear. Study subjects included 93 patients who underwent coronary angiographic examination: 12 patients with coronary artery spasm provoked by ergonovine without organic stenosis (group I), 11 patients who did not demonstrate coronary artery spasm or organic stenosis (group II) and 70 patients with organic coronary artery stenosis (group III). Levels of plasma HDL-cholesterol and apoA-I in group I were similar to those in III but were significantly lower than those in II, although the other plasma lipid parameters were not different among the three groups. The levels of TBARS in plasma and HDL were significantly higher in group I than in II or III (2.94+/-1.56 vs. 1.91+/-0.35 or 2.23+/-0.89 nmol MDA/ml and 1.23+/-1.00 vs. 0.54+/-0.37 or 0.70+/-0.63 nmol MDA/mg protein; P < 0.05), although the levels of TBARS in LDL were not significantly different. In the monitoring curve of diene production during copper-induced lipid peroxidation of HDL, its propagation slope was steeper and levels of maximum diene absorbance was higher in group I as compared with that in II or III, but not found in those of LDL. These results suggested that high susceptibility of HDL to lipid peroxidative modification in group I may contribute to the genesis of coronary artery spasm, and oxidized HDL rather than oxidized LDL is more likely to be related to coronary artery spasm.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920519     DOI: 10.1016/s0021-9150(98)00235-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats.

Authors:  T Kobayashi; T Matsumoto; K Kamata
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects.

Authors:  Kazuhiko Kotani; Naoki Sakane; Masashi Ueda; Shinichi Mashiba; Yasuyuki Hayase; Kokoro Tsuzaki; Toshiyuki Yamada; Alan T Remaley
Journal:  Clin Chim Acta       Date:  2012-09-06       Impact factor: 3.786

3.  HDL enhances oxidation of LDL in vitro in both men and women.

Authors:  T Solakivi; O Jaakkola; A Salomäki; N Peltonen; S Metso; T Lehtimäki; H Jokela; S T Nikkari
Journal:  Lipids Health Dis       Date:  2005-10-20       Impact factor: 3.876

4.  Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Kouichi Miura; Naoshi Arai; Rie Goka; Naoki Morimoto; Shunji Watanabe; Norio Isoda; Hironori Yamamoto; Kazuhiko Kotani
Journal:  Antioxidants (Basel)       Date:  2021-02-04

5.  Aging decreases antioxidant effects and increases lipid peroxidation in the Apolipoprotein E deficient mouse.

Authors:  Taro Honma; Tsuyoshi Tsuduki; Soko Sugawara; Yasuna Kitano; Junya Ito; Ryo Kijima; Mari Tsubata; Kiyotaka Nakagawa; Teruo Miyazawa
Journal:  J Clin Biochem Nutr       Date:  2013-04-09       Impact factor: 3.114

6.  Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women.

Authors:  Joel Perrella; Mauricio Berco; Anthony Cecutti; Alan Gerulath; Bhagu R Bhavnani
Journal:  Lipids Health Dis       Date:  2003-06-20       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.